Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1136 participants.

Also called NCT02273050

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,136 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02273050
Other papers using this trial's data
  • Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial Diabetes, obesity & metabolism, 2018-03 DOI, PubMed 28926170

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02273050. Randomized; quadruple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-08 (actual). Results posted on 2018-02-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Saxagliptin 5 mg
Intervention (Drug)
Placebo 5 mg for Saxagliptin
Intervention (Drug)
Placebo 500 mg for metformin (with titration)
Intervention (Drug)
Metformin 500 mg with titration
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02273050
Content hash
087882a971bccfde4b9406d7bdb66448dd74c6ed7e0d52f150d62e5bd7b64931